Unnamed stage
$38.5m
Cash infusion fast tracks InhaleRx inhaled therapies
InhaleRx has landed $38.5 million from Melbourne venture firm Clendon Biotech Capital to fund the first and second phase trials of two inhaled therapies, including candidates for cancer pain and panic disorder.